161 related articles for article (PubMed ID: 23551230)
1. Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer.
Kubota K; Sato T; Watanabe S; Hosono K; Kobayashi N; Mori R; Taniguchi K; Matsuyama R; Endo I; Nakajima A
Dig Endosc; 2014 Jan; 26(1):77-86. PubMed ID: 23551230
[TBL] [Abstract][Full Text] [Related]
2. A Comparison Between Plastic and Metallic Biliary Stent Placement in Patients Receiving Preoperative Neoadjuvant Chemoradiotherapy for Resectable Pancreatic Cancer.
Nakamura K; Sho M; Akahori T; Nagai M; Nishiwada S; Nakagawa K; Tanaka T; Kichikawa K; Tamamoto T; Hasegawa M; Mitoro A; Yoshiji H; Ikeda N
World J Surg; 2019 Feb; 43(2):642-648. PubMed ID: 30298284
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospective study.
Aadam AA; Evans DB; Khan A; Oh Y; Dua K
Gastrointest Endosc; 2012 Jul; 76(1):67-75. PubMed ID: 22483859
[TBL] [Abstract][Full Text] [Related]
4. Optimal resection area for superior mesenteric artery nerve plexuses after neoadjuvant chemoradiotherapy for locally advanced pancreatic carcinoma.
Einama T; Kamachi H; Tsuruga Y; Sakata T; Shibuya K; Sakamoto Y; Shimada S; Wakayama K; Orimo T; Yokoo H; Kamiyama T; Katoh N; Uchinami Y; Mitsuhashi T; Taketomi A
Medicine (Baltimore); 2018 Aug; 97(31):e11309. PubMed ID: 30075497
[TBL] [Abstract][Full Text] [Related]
5. Self-expanding metal stents (SEMS) for preoperative biliary decompression in patients with resectable and borderline-resectable pancreatic cancer: outcomes in 241 patients.
Siddiqui AA; Mehendiratta V; Loren D; Kowalski T; Fang J; Hilden K; Adler DG
Dig Dis Sci; 2013 Jun; 58(6):1744-50. PubMed ID: 23179157
[TBL] [Abstract][Full Text] [Related]
6. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Thanikachalam K; Damarla V; Seixas T; Dobrosotskaya I; Wollner I; Kwon D; Winters K; Raoufi M; Li J; Siddiqui F; Khan G
Am J Clin Oncol; 2020 Jun; 43(6):435-441. PubMed ID: 32251119
[TBL] [Abstract][Full Text] [Related]
8. Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer.
Sho M; Akahori T; Tanaka T; Kinoshita S; Nagai M; Nishiwada S; Tamamoto T; Nishiofuku H; Ohbayashi C; Hasegawa M; Kichikawa K; Nakajima Y
Langenbecks Arch Surg; 2015 May; 400(4):477-85. PubMed ID: 25929828
[TBL] [Abstract][Full Text] [Related]
9. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes of Biliary Drainage during a Neoadjuvant Therapy for Pancreatic Cancer: Metal versus Plastic Stents.
Kuwatani M; Nakamura T; Hayashi T; Kimura Y; Ono M; Motoya M; Imai K; Yamakita K; Goto T; Takahashi K; Maguchi H; Hirano S;
Gut Liver; 2020 Mar; 14(2):269-273. PubMed ID: 31060118
[TBL] [Abstract][Full Text] [Related]
11. Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer.
Satoi S; Toyokawa H; Yanagimoto H; Yamamoto T; Kamata M; Ohe C; Sakaida N; Uemura Y; Kitade H; Tanigawa N; Inoue K; Matsui Y; Kwon AH
J Gastrointest Surg; 2012 Apr; 16(4):784-92. PubMed ID: 22160780
[TBL] [Abstract][Full Text] [Related]
12. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
[TBL] [Abstract][Full Text] [Related]
13. Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer.
Yabushita Y; Mori R; Taniguchi K; Matsuyama R; Kumamoto T; Sakamaki K; Kubota K; Endo I
Anticancer Res; 2017 May; 37(5):2465-2476. PubMed ID: 28476815
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
Nagakawa Y; Hosokawa Y; Nakayama H; Sahara Y; Takishita C; Nakajima T; Hijikata Y; Kasuya K; Katsumata K; Tokuuye K; Tsuchida A
Cancer Chemother Pharmacol; 2017 May; 79(5):951-957. PubMed ID: 28378027
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01).
Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S;
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735
[TBL] [Abstract][Full Text] [Related]
16. Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment.
Fujii T; Yamada S; Murotani K; Kanda M; Sugimoto H; Nakao A; Kodera Y
Medicine (Baltimore); 2015 Sep; 94(39):e1647. PubMed ID: 26426657
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness and clinical efficacy of biliary stents in patients undergoing neoadjuvant therapy for pancreatic adenocarcinoma in a randomized controlled trial.
Gardner TB; Spangler CC; Byanova KL; Ripple GH; Rockacy MJ; Levenick JM; Smith KD; Colacchio TA; Barth RJ; Zaki BI; Tsapakos MJ; Gordon SR
Gastrointest Endosc; 2016 Sep; 84(3):460-6. PubMed ID: 26972022
[TBL] [Abstract][Full Text] [Related]
18. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
[TBL] [Abstract][Full Text] [Related]
19. Fully covered self-expandable metal stents are effective and safe to treat distal malignant biliary strictures, irrespective of surgical resectability status.
Siddiqui AA; Mehendiratta V; Loren D; Hong SK; Kowalski T
J Clin Gastroenterol; 2011 Oct; 45(9):824-7. PubMed ID: 21921846
[TBL] [Abstract][Full Text] [Related]
20. A Prospective Multicenter Study of Partially Covered Metal Stents in Patients Receiving Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Cancer: BTS-NAC Study.
Saito K; Nakai Y; Isayama H; Yamamoto R; Kawakubo K; Kodama Y; Katanuma A; Kanno A; Itonaga M; Koike K
Gut Liver; 2021 Jan; 15(1):135-141. PubMed ID: 32340436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
